Drug of Abuse Testing Market Size, Share, Growth Analysis, By Drug(Alcohol, Cocaine, Marijuana/Cannabis, LSD), By Sample(Urine, Saliva, Blood, Hair), By Region - Industry Forecast 2024-2031

Global Drug of Abuse Testing Market size was valued at USD 6.7 Billion in 2022 and is poised to grow from USD 7.12 Billion in 2023 to USD 11.61 Billion by 2031, at a CAGR of 6.3% during the forecast period (2024- 2031).

The global drug of abuse testing market is highly competitive and characterized by the presence of several key players. These players are focusing on strategies such as product launches, partnerships, collaborations, and acquisitions to gain a competitive edge. The market is driven by advancements in technology, increasing awareness about drug abuse, and the need for effective testing solutions. Additionally, there is a growing demand for testing products with enhanced sensitivity and specificity to detect a wide range of drugs. Market players are investing in research and development activities to develop innovative testing methods and expand their product portfolios. Furthermore, government initiatives aimed at combating drug abuse and increasing regulatory compliance for drug testing are influencing the market dynamics. The market is also witnessing partnerships between healthcare providers and testing laboratories to streamline the testing process and improve patient outcomes. 'Abbott Laboratories (US)', 'Thermo Fisher Scientific Inc. (US)', 'Siemens Healthineers AG (Germany)', 'F. Hoffmann-La Roche Ltd (Switzerland)', 'Alere Inc. (US)', 'Quest Diagnostics Incorporated (US)', 'Bio-Rad Laboratories, Inc. (US)', 'Drägerwerk AG & Co. KGaA (Germany)', 'Biomerieux SA (France)', 'Shimadzu Corporation (Japan)', 'Randox Laboratories Ltd. (United Kingdom)', 'Psychemedics Corporation (US)', 'Sonic Healthcare (Australia)', 'Merck KGaA (Germany)', 'LabCorp (US)', 'MP Biomedicals LLC (US)', 'Omega Laboratories, Inc. (US)', 'Express Diagnostics International Inc. (US)', 'Sciteck, Inc. (US)', 'Premier Biotech Inc. (US)'

The growing production, consumption, and trade of both new and illicit drugs are expected to drive the demand for Drug of Abuse (DoA) testing, thereby fueling the growth of the industry. According to the United Nations Office on Drugs and Crime's World Drug Report 2017, there was an annual prevalence of 5.3% for illicit drug use, with 255 million users in 2015. This significant number of drug users underscores the need for DoA testing, which will propel the market forward. Government initiatives aimed at raising awareness about drug abuse and increasing organizational compliance for DoA testing will also contribute to the overall growth of the market. Additionally, there is a high demand for testing products that offer enhanced specificity and sensitivity to detect designer drugs, further bolstering the industry's expansion.

Increasing Adoption of Point-of-Care Testing: There is a growing trend towards point-of-care testing, which allows for quick and convenient drug testing at the bedside or in non-laboratory settings. This trend is driven by the need for rapid results and the ability to perform tests in remote or decentralized locations.

North America has emerged as the leading market, capturing a significant share of 39.1%. This can be attributed to prominent players in the region implementing extensive expansion strategies and the increasing prevalence of substance abuse, along with government initiatives to combat it. However, the COVID-19 pandemic has led to a rise in substance use disorders, which is expected to drive the demand for drug abuse testing services. On the other hand, the imposition of nationwide lockdowns has resulted in reduced demand for workplace drug testing services, leading to slower market growth in the region.